Home・Akciju saraksts・Protagonist Therapeutics Inc

Protagonist Therapeutics Inc

Slēgts

SektorsVeselības aprūpe

135.94 2.91

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

132.13

Max

137.77

Galvenie mērījumi
By Trading Economics
Ienākumi	-82M 3.8M
Pārdošana	49M 56M
P/E Sektora vidējais	131.197 64.641
EPS	0.05
Peļņas marža	6.711
Darbinieki	131
EBITDA	46M 2.7M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	-0.88% downside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 11. aug.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.3B 8.7B
Iepriekšējā atvēršanas cena	133.03
Iepriekšējā slēgšanas cena	135.94

Ziņu noskaņojums

By Acuity

42%

58%

133 / 340 Rangs Healthcare

Protagonist Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. aug. 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

2026. g. 31. jūl. 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

2026. g. 30. jūl. 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

2026. g. 29. jūl. 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

2026. g. 28. jūl. 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

2026. g. 27. jūl. 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

2026. g. 22. jūl. 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

2026. g. 21. jūl. 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

2026. g. 20. jūl. 19:41 UTC

News

Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Salīdzinājums

Cenas izmaiņa

Protagonist Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

-0.88% uz leju

Prognoze 12 mēnešiem

Vidējais 131.11 USD -0.88%

Augstākais 165 USD

Zemākais 110 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Protagonist Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Protagonist Therapeutics Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

133 / 340 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.